UCSD's Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses 'Xafty' as 'The weapon to end the virus war.' - Announces ...
Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone - ...
Invivyd has launched its DECLARATION Phase 3 pivotal trial for VYD2311, a monoclonal antibody designed as an alternative to ...
Long COVID affects an estimated 65 million people worldwide and can damage the brain, heart, blood vessels, and immune system ...
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...
It was the priciest biotech startup sale in North Carolina history. Now five years under Bayer, AskBio advances more AAV gene ...
The vaccines subsector received a big fillip from Covid, but its potential extends far beyond combating pandemics. Dr Mike ...
SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a ...
Researchers found that in mouse models (in a lab), SARS‑CoV‑2 mRNA vaccination triggered strong type I interferon signals, ...
BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapiesExpected 2026 oncology ...
Aiming to facilitate large-scale indigenous manufacturing, this device will secure regulatory approvals, and facilitate the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback